|
1
|
Li Z, Chen Z, Hu G and Jiang Y: Roles of
circular RNA in breast cancer: Present and future. Am J Transl Res.
11:3945–3954. 2019.PubMed/NCBI
|
|
2
|
DeSantis C, Ma JM, Bryan L and Jemal A:
Breast Cancer Statistics, 2013. CA Cancer J Clin. 64:52–62. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Palma G, Frasci G, Chirico A, Esposito E,
Siani C, Saturnino C, Arra C, Ciliberto G, Giordano A and D'Aiuto
M: Triple negative breast cancer: Looking for the missing link
between biology and treatments. Oncotarget. 6:26560–26574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andreopoulou E, Schweber SJ, Sparano JA
and McDaid HM: Therapies for triple negative breast cancer. Expert
Opin Pharmacother. 16:983–998. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rivankar S: An overview of doxorubicin
formulations in cancer therapy. J Cancer Res Ther. 10:853–858.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joensuu H and Gligorov J: Adjuvant
treatments for triple-negative breast cancers. Ann Oncol. 23 (Suppl
6):vi40–vi45. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yagata H, Kajiura Y and Yamauchi H:
Current strategy for triple-negative breast cancer: Appropriate
combination of surgery, radiation, and chemotherapy. Breast Cancer.
18:165–173. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li YW and Sarkar FH: MicroRNA targeted
therapeutic approach for pancreatic cancer. Int J Biol Sci.
12:326–337. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rizzo S, Cangemi A, Galvano A, Fanale D,
Buscemi S, Ciaccio M, Russo A, Castorina S and Bazan V: Analysis of
miRNA expression profile induced by short term starvation in breast
cancer cells treated with doxorubicin. Oncotarget. 8:71924–71932.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ouyang M, Li Y, Ye S, Ma J, Lu L, Lv W,
Chang G, Li X, Li Q6, Wang S5 and Wang W: MicroRNA profiling
implies new markers of chemoresistance of triple-negative breast
cancer. PLoS One. 9:e962282014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sha LY, Zhang Y, Wang W, Sui X, Liu SK,
Wang T and Zhang H: MiR-18a upregulation decreases Dicer expression
and confers paclitaxel resistance in triple negative breast cancer.
Eur Rev Med Pharmacol Sci. 20:2201–2208. 2016.PubMed/NCBI
|
|
13
|
O'Brien K, Lowry MC, Corcoran C, Martinez
VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA and
O'Driscoll L: miR-134 in extracellular vesicles reduces
triple-negative breast cancer aggression and increases drug
sensitivity. Oncotarget. 6:32774–32789. 2015.PubMed/NCBI
|
|
14
|
Niu J, Xue A, Chi Y, Xue J, Wang W, Zhao
Z, Fan M, Yang CH, Shao ZM, Pfeffer LM, et al: Induction of
miRNA-181a by genotoxic treatments promotes chemotherapeutic
resistance and metastasis in breast cancer. Oncogene. 35:1302–1313.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cao K, Li J and Chen J: microRNA-33a-5p
increases radiosensitivity by inhibiting glycolysis in melanoma.
Oncotarget. 8:83660–83672. 2017.PubMed/NCBI
|
|
16
|
Meng W, Tai Y, Zhao H, Fu B, Zhang T, Liu
W, Li H, Yang Y, Zhang Q, Feng Y and Chen G: Downregulation of
miR-33a-5p in hepatocellular carcinoma: A possible mechanism for
chemotherapy resistance. Med Sci Monit. 23:1295–1304. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou W, Fang H, Wu Q, Wang X, Liu R, Li F,
Xiao J, Yuan L, Zhou Z, Ma J, et al: Ilamycin E, a natural product
of marine actinomycete, inhibits triple-negative breast cancer
partially through ER stress-CHOP-Bcl-2. Int J Biol Sci.
15:1723–1732. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mitra A, Mishra L and Li S: EMT, CTCs and
CSCs in tumor relapse and drug-resistance. Oncotarget.
6:10697–10711. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Du B and Shim JS: Targeting
epithelial-mesenchymal transition (EMT) to overcome drug resistance
in cancer. Molecules. 21(pii): E9652016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
22
|
Fang L, Gao L, Xie L and Xiao G: GC7
enhances cisplatin sensitivity via STAT3 signaling pathway
inhibition and eIF5A2 inactivation in mesenchymal phenotype oral
cancer cells. Oncol Rep. 39:1283–1291. 2018.PubMed/NCBI
|
|
23
|
Lou B, Fan J, Wang K, Chen W, Zhou X,
Zhang J, Lin S, Lv F and Chen Y: N1-guanyl-1,7-diaminoheptane (GC7)
enhances the therapeutic efficacy of doxorubicin by inhibiting
activation of eukaryotic translation initiation factor 5A2 (eIF5A2)
and preventing the epithelial-mesenchymal transition in
hepatocellular carcinoma cells. Exp Cell Res. 319:2708–2717. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lien MY, Liu LC, Wang HC, Yeh MH, Chen CJ,
Yeh SP, Bai LY, Liao YM, Lin CY, Hsieh CY, et al: Safety and
efficacy of pegylated liposomal doxorubicin-based adjuvant
chemotherapy in patients with stage I–III triple-negative breast
cancer. Anticancer Res. 34:7319–7326. 2014.PubMed/NCBI
|
|
26
|
Xue F, Liu Y, Zhang H, Wen Y, Yan L, Tang
Q, Xiao E and Zhang D: Let-7a enhances the sensitivity of
hepatocellular carcinoma cells to cetuximab by regulating STAT3
expression. Onco Targets Ther. 9:7253–7261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Li Q, Xia X, Ji J, Ma J, Tao L, Mo L and
Chen W: MiR-199a-3p enhances cisplatin sensitivity of
cholangiocarcinoma cells by inhibiting mTOR signaling pathway and
expression of MDR1. Oncotarget. 8:33621–33630. 2017.PubMed/NCBI
|
|
28
|
Wang J, Yang M, Li Y and Han B: The role
of MicroRNAs in the chemoresistance of breast cancer. Drug Dev Res.
76:368–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mi W, Shi Q, Chen X, Wu T and Huang H:
miR-33a-5p modulates TNF-α-inhibited osteogenic differentiation by
targeting SATB2 expression in hBMSCs. FEBS Lett. 590:396–407. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang J, Wang D, Xiong J, Chen L and Huang
J: MicroRNA-33a-5p suppresses growth of osteosarcoma cells and is
downregulated in human osteosarcoma. Oncol Lett. 10:2135–2141.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Jia G, Qu Y, Du Q and Liu B and Liu
B: Long non-coding RNA (LncRNA) HOXA11-AS promotes breast cancer
invasion and metastasis by regulating epithelial-mesenchymal
transition. Med Sci Monit. 23:3393–3403. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao M, Ang L, Huang J and Wang J:
MicroRNAs regulate the epithelial-mesenchymal transition and
influence breast cancer invasion and metastasis. Tumour Biol.
39:10104283176916822017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Banyard J and Bielenberg DR: The role of
EMT and MET in cancer dissemination. Connect Tissue Res.
56:403–413. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: Emt: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen WC, Lai YA, Lin YC, Ma JW, Huang LF,
Yang NS, Ho CT, Kuo SC and Way TD: Curcumin suppresses
doxorubicin-induced epithelial-mesenchymal transition via the
inhibition of TGF-β and PI3K/AKT signaling pathways in
triple-negative breast cancer cells. J Agric Food Chem.
61:11817–11824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Blanchard Z, Paul BT, Craft B and ElShamy
WM: BRCA1-IRIS inactivation overcomes paclitaxel resistance in
triple negative breast cancers. Breast Cancer Res. 17:52015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mohr AM and Mott JL: Overview of microRNA
biology. Semin Liver Dis. 35:3–11. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bai HY, Liao YJ, Cai MY, Ma NF, Zhang Q,
Chen JW, Zhang JX, Wang FW, Wang CY and Chen WH: Eukaryotic
initiation factor 5A2 contributes to the maintenance of CD133(+)
hepatocellular carcinoma cells via the c-Myc/microRNA-29b axis.
Stem Cells. 36:180–191. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang X, Jin Y, Zhang H, Huang X, Zhang Y
and Zhu J: MicroRNA-599 inhibits metastasis and
epithelial-mesenchymal transition via targeting EIF5A2 in gastric
cancer. Biomed Pharmacother. 97:473–480. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu G, Shao G, Pan Q, Sun L, Zheng D, Li M,
Li N, Shi H and Ni Y: MicroRNA-9 regulates non-small cell lung
cancer cell invasion and migration by targeting eukaryotic
translation initiation factor 5A2. Am J Transl Res. 9:478–488.
2017.PubMed/NCBI
|
|
41
|
Tian SB, Yu JC, Liu YQ, Kang WM, Ma ZQ, Ye
X and Yan C: MiR-30b suppresses tumor migration and invasion by
targeting EIF5A2 in gastric cancer. World J Gastroenterol.
21:9337–9347. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Tsang FH, Au V, Lu WJ, Shek FH, Liu AM,
Luk JM, Fan ST, Poon RT and Lee NP: Prognostic marker microRNA-125b
inhibits tumorigenic properties of hepatocellular carcinoma cells
via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci.
59:2477–2487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei YX, Chen G, You L and Zhao YP:
Expression of eukaryotic translation initiation factor 5A2 in
pancreatic adenocarcinoma and its correlation with the prognosis.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 35:634–638. 2013.(In Chinese).
PubMed/NCBI
|
|
44
|
Liu RR, Lv YS, Tang YX, Wang YF, Chen XL,
Zheng XX, Xie SZ, Cai Y, Yu J and Zhang XN: Eukaryotic translation
initiation factor 5A2 regulates the migration and invasion of
hepatocellular carcinoma cells via pathways involving reactive
oxygen species. Oncotarget. 7:24348–24360. 2016.PubMed/NCBI
|
|
45
|
He LR, Zhao HY, Li BK, Liu YH, Liu MZ,
Guan XY, Bian XW, Zeng YX and Xie D: Overexpression of eIF5A-2 is
an adverse prognostic marker of survival in stage I non-small cell
lung cancer patients. Int J Cancer. 129:143–150. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Meng QB, Kang WM, Yu JC, Liu YQ, Ma ZQ,
Zhou L, Cui QC and Zhou WX: Overexpression of eukaryotic
translation initiation factor 5A2 (EIF5A2) correlates with cell
aggressiveness and poor survival in gastric cancer. PLoS One.
10:e01192292015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bao Y, Lu Y, Wang X, Feng W, Sun X, Guo H,
Tang C, Zhang X, Shi Q and Yu H: Eukaryotic translation initiation
factor 5A2 (eIF5A2) regulates chemoresistance in colorectal cancer
through epithelial mesenchymal transition. Cancer Cell Int.
15:1092015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yang H, Li XD, Zhou Y, Ban X, Zeng TT, Li
L, Zhang BZ, Yun J, Xie D, Guan XY and Li Y: Stemness and
chemotherapeutic drug resistance induced by EIF5A2 overexpression
in esophageal squamous cell carcinoma. Oncotarget. 6:26079–26089.
2015.PubMed/NCBI
|
|
49
|
Yang J, Yu H, Shen M, Wei W, Xia L and
Zhao P: N1-guanyl-1,7-diaminoheptane sensitizes bladder cancer
cells to doxorubicin by preventing epithelial-mesenchymal
transition through inhibition of eukaryotic translation initiation
factor 5A2 activation. Cancer Sci. 105:219–227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu Y, Du F, Chen W, Yao M, Lv K and Fu P:
EIF5A2 is a novel chemoresistance gene in breast cancer. Breast
Cancer. 22:602–607. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu Y, Liu R, Fu P, Du F, Hong Y, Yao M,
Zhang X and Zheng S: N1-Guanyl-1,7-diaminoheptane sensitizes
estrogen receptor negative breast cancer cells to doxorubicin by
preventing epithelial-mesenchymal transition through inhibition of
eukaryotic translation initiation factor 5a2 activation. Cell
Physiol Biochem. 36:2494–2503. 2015. View Article : Google Scholar : PubMed/NCBI
|
